Navigation
banner

Antibody & Protein Therapeutics Summit

2017-11-182018-03-252018-02-25
EARLY BIRD DISCOUNT! Register by Feb 25, 2018 to receive 30% off your registration!
Or Register 3 for the price of 2 with the coupon code rcdvb!


The 2018 speaker list is currently being formed.

Please come back and visit this page for update.

BELOW ARE THE SPEAKERS FROM 2017

PLENARY KEYNOTE SPEAKERS
Christian Schoneich

Christian Schoneich
Takeru Higuchi Distinguished Professor and Chair, Department of Pharmaceutical Chemistry
University of Kansas
Christian Schoneich
Takeru Higuchi Distinguished Professor and Chair, Department of Pharmaceutical Chemistry
University of Kansas
 
About Speaker:

Dr. Schöneich is the Takeru Higuchi Distinguished Professor for Bioanalytical Chemistry and Chair of the Department of Pharmaceutical Chemistry at The University of Kansas. He received his Diploma in Chemistry from the Free University Berlin, Germany, in 1987. Between 1987 and 1991 he worked in the Department of Radiation Chemistry at the Hahn-Meitner Institute for Nuclear Research in Berlin, Germany. He received his Ph.D. in Chemistry in 1990 from the Technical University Berlin, Germany. He joined the Department of Pharmaceutical Chemistry at The University of Kansas as a post-doctoral fellow in 1991, and as a faculty member in 1992; in 2004, he was a Visiting Professor at the ETH Zürich, Switzerland.

Sally Ward

Sally Ward
Professor, Department of Molecular and Cellular Medicine
Texas A&M Health Science Center
Sally Ward
Professor, Department of Molecular and Cellular Medicine
Texas A&M Health Science Center
 
About Speaker:

Sally Ward received the Ph.D. degree from the Department of Biochemistry, Cambridge University, Cambridge, U.K. in 1985. From 1985-1988 she was a Research Fellow at Gonville and Caius College whilst working at the Department of Biochemistry, Cambridge University. From 1988 to 1990, she held the Stanley Elmore Senior Research Fellowship at Sidney Sussex College and carried out research in Sir Greg Winter’s laboratory at the MRC Laboratory of Molecular Biology in Cambridge. In 1990 she joined the University of Texas Southwestern Medical Center, Dallas, as an Assistant Professor. Since 2002, she was a Professor in the Department of Immunology at the same institution and in 2004 was appointed to the Paul and Betty Meek-FINA Professorship in Molecular Immunology. In 2014 she moved as a Professor to Texas A&M Health Science Center. Her current research interests include understanding FcRn function in mouse and man, with a particular focus on using a combination of fluorescence imaging, protein engineering and in vivo studies to understand the factors that regulate the distribution and transport of antibodies. A second area of interest is to characterize the behavior, at the subcellular level, of molecular targets in cancer. Her work includes the development of antibody-based therapies in mouse models of multiple sclerosis, arthritis and cancer. She is a member of the Board of Distinguished Advisors in the Antibody Society and serves on the editorial boards of mAbs and Protein Engineering, Design and Selection.

John Charles Williams

John Charles Williams
Professor, Department of Molecular Medicine
City of Hope
John Charles Williams
Professor, Department of Molecular Medicine
City of Hope
 
About Speaker:

John is professor of molecular medicine at the Beckman Research Institute of the City of Hope, where he also serves as a member of the Developmental Cancer Therapeutics Program as well as Co-Director of the Drug Discovery and Structural Biology Core.

The main focus of John’s research centers on the application of structural and biophysical methods to understand the biological role of multivalency and energy additivity on multicomponent, macromolecular complexes and how to manipulate these properties to develop novel, highly specific agonists and antagonists. His lab also discovered the meditope binding site while investigating alternative methods of modulating properties of protein therapeutics.

John earned his B.S. in chemistry from the University of California at Santa Cruz and his Ph.D. in chemistry from Columbia University. He was an Alexander von Humboldt postdoctoral fellow at the European Molecular Biology Laboratories in Heidelberg, Germany and an HHMI and Leukemia and Lymphoma Society Special Fellow at Columbia-Presbyterian Medical Center.

PLENARY SPEAKERS
Ezio Bonvini

Ezio Bonvini
Senior Vice President of Research
Macrogenics
Ezio Bonvini
Senior Vice President of Research
Macrogenics
 
About Speaker:

Dr. Bonvini, Senior Vice President, Research and Chief Scientific Officer, joined Macrogenics in June 2003. From 1985 to 2003, Dr. Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is responsible for regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982 to 1984, Dr. Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr. Bonvini received a Diploma in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.

Owen Fields

Owen Fields
Vice President Regulatory Strategy
Pfizer
Owen Fields
Vice President Regulatory Strategy
Pfizer
 
About Speaker:

Owen joined Pfizer with the merger of Pfizer and Wyeth. Owen joined Wyeth in 1995, and was responsible for providing regulatory strategy advice for many of Wyeth’s biological products. Prior to Wyeth, Owen served as a review team leader at the United States Food and Drug Administration, where he helped develop and shape US regulatory policy towards food biotechnology. Owen has a BS in Biochemistry and a minor in mathematics from Wichita State University and received his Ph.D. from the Department of Molecular and Cellular Biology at the University of California, Berkeley in 1991.

Elad Firnberg

Elad Firnberg
CEO
Revolve Biotech
Elad Firnberg
CEO
Revolve Biotech
 
About Speaker:

Dr. Firnberg is CEO and co-founder of Revolve Biotechnologies, a biotech company specializing in DNA library construction for antibody and protein engineering. Dr. Firnberg received his Ph.D. in Chemical and Biomolecular Engineering at Johns Hopkins University, where his research focused on understanding protein evolution through mapping enzyme mutational fitness landscapes. At Revolve he has launched the company's library generation service using its patented PFunkel mutagenesis technology. 

Michael Gallo

Michael Gallo
President of Research
Innovative Targeting Solutions
Michael Gallo
President of Research
Innovative Targeting Solutions
 
About Speaker:

Michael Gallo, President of Innovative Targeting Solutions Inc. has been an instrumental contributor to the use and development of transgenic mice for the discovery of human therapeutic antibodies. He was part of the original scientific team at Cell Genesys that created XenoMouse, the premier transgenic mouse technology for generating fully human antibodies, and spun-off from Cell Genesys in 1996 to start Abgenix.  As the Vice President of Research at Abgenix Inc. and subsequently Amgen British Columbia, Michael oversaw numerous collaborations including AstraZeneca, Pfizer, Abbot, Curagen, Milleneum, and Dendreon. 

Amy	Grenham

Amy Grenham
Director, Regulatory Affairs
MedImmune
Amy Grenham
Director, Regulatory Affairs
MedImmune
 
About Speaker:

Amy Grenham serves as a Global Regulatory Lead at MedImmune/AstraZeneca responsible for regulatory strategy development to support all phases of drug development. She has more than 15 years’ experience in the biotechnology field with a focus on development of protein therapeutics including vaccines for infectious diseases. Amy has a BS in Biology from the University of Connecticut and MS from the University of Michigan Department of Molecular and Cellular Biology and has earned Regulatory Affairs Certification (US, Europe).

Bill Harriman

Bill Harriman
CSO, Co-Founder
Crystal Bioscience
Bill Harriman
CSO, Co-Founder
Crystal Bioscience
 
About Speaker:

Bill Harriman, Ph.D., is a co-founder and Chief Scientific Officer of Crystal Bioscience, which was founded in 2008 with the mission to create a platform for antibody discovery featuring wild-type and engineered birds. His prior experience at biotech and pharma companies including Trellis Bioscience, Roche, and Abgenix involved roles as project manager, antibody group leader, and technology developer.

Lin He

Lin He
Principal Application Scientist
Bioinformatics Solutions Inc
Lin He
Principal Application Scientist
Bioinformatics Solutions Inc
 
About Speaker:

Dr. Lin He is the Principal Application Scientist of Bioinformatics Solutions Inc. (BSI), which is one of the leading suppliers of mass spectrometry data analysis software and service. He graduated from University of Waterloo, Canada, as a Ph.D. in Bioinformatics and then joined the Yates Lab at The Scripps Research Institute as a Research Associate. He joined in BSI in 2015, mainly contributing to the protein de novo sequencing service and software development for antibody protein characterization.

Syd Johnson

Syd Johnson
Vice President, Antibody Engineering
Macrogenics
Syd Johnson
Vice President, Antibody Engineering
Macrogenics
 
About Speaker:
Srinath Kasturirangan

Srinath Kasturirangan
Scientist, Antibody Discovery and Protein Engineering
MedImmune
Srinath Kasturirangan
Scientist, Antibody Discovery and Protein Engineering
MedImmune
 
About Speaker:

I have been working as a Scientist I at Medimmune since November 2010. My primary responsibilities are generation and characterization of novel bispecific antibodies, antibody engineering for stability and half life improvements and technology development. Prior to working at Medimmune, I got my PhD in Bioengineering at Arizona State Univerisity, working on Antibody based therapeutics for Alzheimer's disease in the lab of Dr Mike Sierks. At ASU, we developed a novel biopanning technique combining the imaging capability of atomic force microscopy with phage display to isolate scFv against low concentrations of specific brain derived oligomers of beta amyloid. I have also worked on catalytic antibodies that can cleave beta amyloid at specific sites. I have several publications in peer reviewed journals and patents.

Emily Leproust

Emily Leproust
Chief Executive Officer
Twist Bioscience
Emily Leproust
Chief Executive Officer
Twist Bioscience
 
About Speaker:

Emily Leproust, Ph.D. serves as CEO of Twist Bioscience. Dr. Leproust is disrupting the process of gene synthesis to enable exponential growth of synthetic biology applications. She was named one of Foreign Policy’s 100 Leading Global Thinkers and one of the most creative people in business by Fast Company.

Cinthia Pastuskovas

Cinthia Pastuskovas
Senior Scientist, Pharmacokinetics and Drug Metabolism
Amgen
Cinthia Pastuskovas
Senior Scientist, Pharmacokinetics and Drug Metabolism
Amgen
 
About Speaker:

Cinthia Pastuskovas received her PhD in Neurosciences at the University of Cordoba, Argentina and continued her line of research as a postdoctoral fellowship at the University of Iowa investigating the neuronal mechanisms activated under conditions of sodium depletion in pharmacological rat models of sodium depletion. In 2002 Cinthia was hired by Genentech, Inc to support target validation and therapeutic antibody selection by characterizing in vitro/in vivo kinetics of absorption, distribution, catabolism, and excretion of large molecules for various therapeutic areas.

Peter Slavny

Peter Slavny
Project Leader and Co-Founder
IONTAS
Peter Slavny
Project Leader and Co-Founder
IONTAS
 
About Speaker:

Peter received a PhD in biochemistry from the John Innes Centre in Norwich, UK. He subsequently joined the McCafferty laboratory at the University of Cambridge, UK, as a post-doctoral researcher working on therapeutic antibody discovery by phage display. He was a co-founder of IONTAS ltd in 2012, where he is currently a Project Leader running antibody discovery campaigns to diverse and challenging target classes. 

Ernest Smith

Ernest Smith
Senior Vice President, Research & CSO
Vaccinex
Ernest Smith
Senior Vice President, Research & CSO
Vaccinex
 
About Speaker:

I joined Vaccinex at its inception in 1997 and was a key developer of its core cDNA library and antibody discovery technologies. In my current position, I am responsible for and contributes to the company’s research and technology development projects, and am a member of the clinical development team. I have a Ph.D. in Microbiology and Immunology from the University of Rochester.

Wyatt Strutz

Wyatt Strutz
Senior Application Specialist
NanoTemper Technologies
Wyatt Strutz
Senior Application Specialist
NanoTemper Technologies
 
About Speaker:

Wyatt Strutz received a dual B.Sc & M.Sc in Biomedical Engineering from Drexel University, located in Philadelphia, PA. Before joining NanoTemper Technologies in 2012, he was developing cartilage scaffolds dually between Drexel University and University of Pennsylvania School of Medicine. He also has experience developing enzymatic and cell-based assays for global pharmaceutical companies. Currently, Wyatt leads a team in the rapidly expanding North American biophysical market.

Omid Vafa

Omid Vafa
Chief Business Officer
TENEObio
Omid Vafa
Chief Business Officer
TENEObio
 
About Speaker:

Omid Vafa is the Chief Business Officer at Teneobio, Inc. He has more that 15 years of global business and scientific experience in biotechnology and pharmaceutical drug discovery, asset evaluation, transactions and licensing. Prior to joining TeneoBio, Omid was the Director of Strategy and Scientific Partnerships at Janssen Pharmaceutical Companies of Johnson and Johnson and the Biotechnology and Oncology Lead at the London Innovation Center of J&J. Omid earned his doctorate at Georgetown University, his MBA from the Villanova University School of Business, and his B.S. from the University of California at Irvine. He completed his post-doctoral fellowships at The Scripps Research Institute (TSRI) and the Salk Institute for Biological Studies in La Jolla, California. 

Dan Zhang

Dan Zhang
Chairman and CEO
Fountain Medical Development
Dan Zhang
Chairman and CEO
Fountain Medical Development
 
About Speaker:

Dr. Dan Zhang is the Chairman and CEO of Fountain Medical Development Ltd, a full-service clinical CRO with 1300 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia and USA.

Dr. Zhang was the Head of Clinical Development at Sigma-Tau Research Inc, He was a vice president at the Quintiles Transnational Corp. and the Chairman of the Board, Quintiles Medical Development (Shanghai) Company Ltd.,

Dr. Zhang is a member of grant application review committee for National Key Drug Development Fund of China, and is also a consultant for the China Food and Drug Administration (CFDA). He is chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association. He was a member of the Overseas Expert Committee on New Drug R&D for the Ministry of Science and Technology of China, and was the secretary-general of the Association of “Thousand Talent” Expert

Dr. Zhang received his pre-med training from Peking University and received his M.D. from Peking Union Medical College. He then went to the Harvard School of Public Health and received an MPH in health policy and management. Then he went to the Wharton Business School of the University of Pennsylvania, where he obtained his master’s degree in healthcare management in 1998.

Antibodies in Oncology & Beyond 2017
DISTINGUISHED SPEAKERS
Sofia Casares

Sofia Casares
Director Pre-Clinical Research & Concept Development
Walter Reed Army Institute of Research
Sofia Casares
Director Pre-Clinical Research & Concept Development
Walter Reed Army Institute of Research
 
About Speaker:

Dr. Sofia Casares is the Director of Pre-Clinical Research in the Division of Malaria at the Naval Medical Research Center/Walter Reed Army Institute of Research. She obtained her PhD in 1991 from the Universidad Autonoma de Madrid, received doctoral trainings at California Institute of Biological Research and at Mount Sinai School of Medicine (MSSM) followed by a Faculty appointment in the Department of Microbiology, MSSM with research focused in the field of autoimmunity and immunotherapy. Her laboratory at the Naval Medical Research center/Walter Reed Army Institute of Research generated the humanized HLA-expressing DRAGA mouse model that sustains infection with Plasmodium falciparum malaria, HIV, dengue, and scrub typhus, and also elicit immune responses upon vaccination. The humanized mouse models are currently being used for generation of human therapeutic monoclonal antibodies against infectious diseases.

Jacob Glanville

Jacob Glanville
CSO
Distributed Bio Inc.
Jacob Glanville
CSO
Distributed Bio Inc.
 
About Speaker:

Jake grew up in a village in the highlands of Guatemala, but returned to the first world to solve problems in computational immunology. He went from the Tzutujile village of Santiago Atitlan in Guatemala to an undergraduate in Genetics, Genomics and Development research at UC Berkeley, to become Principal Scientist at Pfizer, to entering into and in the process of completing a PhD in Computational and Systems Immunology at Stanford University School of Medicine, and now Chief Science Officer and Co-founder of Distributed Bio.

He is a field leader in antibody, TCR and pMHC repertoire algorithms and methods development, having published multiple early defining manuscripts and patents to combine next generation sequencing, protein engineering, immunology, and algorithm development to interrogate antibody repertoires and optimize their responses towards therapeutic applications. He personally developed the core algorithms that allowed Distributed Bio to become profitable within the first year of founding, with clients and collaborators now including 7 of the top 10 pharma, multiple research institutions, the Stanford Hospital Blood and Marrow transplant clinic and over 30 biotechnology and academic institutions internationally.

As a UC Berkeley undergraduate, Jacob Glanville performed research in two academic laboratories, Dr. Glenys Thomson's HLA Population Genetics laboratory, and Dr. Sjolander's Berkeley Phylogenomics Group, where in the latter, as an undergrad, he begin publishing first-author publications. In March 2008, Jacob was recruited to Pfizer's Rinat Antibody Therapeutics research facility, he developed novel computational immunology methods for characterizing and optimizing functions of the adaptive immune system, engineering molecules for drug development, and was promoted every year for four consecutive years to become Principal Scientist by 2012. In 2012 he left Pfizer with a vision to create Distributed Bio and bring routine antibody repertoire analytics to the masses.

In parallel with co-leading the now-profitable Distributed Bio, he is working to complete a PhD in Computational and Systems Immunology at Stanford University, coadvised by Mark Davis and Scott Boyd and in collaboration with multiple other laboratories including the Nadeau, Maecker, Martinez, Engleman, and Chien labs.

Veronique Lecault

Veronique Lecault
Co-Founder
AbCellera
Veronique Lecault
Co-Founder
AbCellera
 
About Speaker:

Dr. Lecault is co-founder of AbCellera, a Canadian biotechnology company focused on the discovery of therapeutic antibodies from natural immune repertoires. She received her PhD in Chemical and Biological Engineering from the University of British Columbia, where she trained under the supervision of Dr. James Piret and Dr. Carl Hansen. During her studies she developed a microfluidic mammalian cell culture platform that allowed for monitoring of thousands of single hematopoietic stem cells at once, and for clonal selection of high-secreting cell lines for antibody production. Prior to this, she simultaneously obtained a B.Sc. in Biochemistry/Biotechnology and a B.A.Sc. in Chemical Engineering, summa cum laude, from the University of Ottawa.

Liqin Liu

Liqin Liu
Associate Director, Cell Biology and Immunology
MacroGenics
Liqin Liu
Associate Director, Cell Biology and Immunology
MacroGenics
 
About Speaker:

Liqin Liu is an Associate Director at MacroGenics Inc. She received her PhD from Medical College of Ohio and performed post-doctoral training at Harvard Medical School. Before joining MacroGenics, Liqin worked at Amgen as a Senior Scientist, successfully leading several programs spanning antibody-drug-conjugates, bispecific antibody and small molecule drug discovery and development. During the last four years working at MacroGenics, she has led teams participating in discovery level and middle or late-stage cancer immunotherapy DART (Dual Affinity Re-Targeting) bispecific antibody programs, advancing several programs from preclinical discovery into early clinical development. Liqin has numerous scientific publications on peer reviewed journals and has been involved in several patent filings as a co-inventor.

Anne Ljungars

Anne Ljungars
Scientist, Preclinical Research
BioInvent International AB
Anne Ljungars
Scientist, Preclinical Research
BioInvent International AB
 
About Speaker:

Anne Ljungars has 15+ years of experience in biotech industry and antibody drug development. She currently has a position in the Antibody Discovery team in the Preclinical Research department at BioInvent, Lund, Sweden. As a senior member of this team she has coordinated discovery efforts in several antibody drug projects, presently in preclinical or clinical development. She is responsible for high-throughput screening assays and the automated screening platforms at BioInvent and has been a key person in development of the phenotypic antibody-target discovery platform F.I.R.S.T™.

Janos Luka

Janos Luka
Ph.D. Scientist, Bacterial Diseases
Walter Reed Army Institute of Research
Janos Luka
Ph.D. Scientist, Bacterial Diseases
Walter Reed Army Institute of Research
 
About Speaker:

Janos Luka received his Ph.D. in Tumor virology and Immunology at Karolinska Institutet in Stockholm, Sweden, where his research was concentrated on Epstein - Barr virus and its role in B-cell lymphomas. He completed a postdoctoral fellowship at Mayo Clinic Rochester, Minnesota, where he developed the first commercialized ELISA test for detection of EBV associated diseases. He moved to Georgetown University and worked on lymphotropic herpesviruses and developed several diagnostic assays for detection of lymphotropic herpes viruses. As Associate Professor at At Eastern Virginia Medical school he established a CAP accredited diagnostic laboratory focused on viral infections, which he directed for nine years. In 2003 he established a biotechnology company and was associated with several biotechnology companies to characterize and produce monoclonal antibodies for clinical trials. He has co-authored over 100 peer-reviewed papers and has extensive management, and business experience. At present his research work is focused on diagnostic assay development for bacterial and fungal infections and developed a unique method to produce fully human therapeutic monoclonal antibodies against drug resistant infectious diseases.

Fan Yang

Fan Yang
Associate Director, Research & Discovery
Amunix
Fan Yang
Associate Director, Research & Discovery
Amunix
 
About Speaker:

Originally trained as a structural biologist at Pamela Bjorkman's lab at Caltech, Fan is now leading the discovery effort at Amunix on multiple partner and internal projects based on its proprietary XTEN technology, including the novel ProTIA platform for oncology, which she will share with you today.

Antibody Drug Conjugates 2017
DISTINGUISHED SPEAKERS
Daryl Drummond

Daryl Drummond
Head of Research
Merrimack Pharmaceuticals
Daryl Drummond
Head of Research
Merrimack Pharmaceuticals
 
About Speaker:

Daryl Drummond currently serves as the Head of Research for Merrimack Pharmaceuticals, where he oversees the discovery efforts for Merrimack’s Nanotherapeutics and Biologics-based therapeutics. Dr. Drummond received a Ph.D. degree in Biochemistry from Indiana University in 1997, with an emphasis on membrane biochemistry and biophysics, and later did a postdoc under the renowned father of lipid-based drug delivery systems, Demetrios Papahadjopoulos at UCSF and California Pacific Medical Center. Dr. Drummond was one of two principle inventors for many of Merrimack's nanotechnology-based drugs and platform technologies, most notably Onivyde, a highly stabilized liposomal formulation of irinotecan. He joined Merrimack in October of 2009 following the merger of Merrimack with Hermes Biosciences. Dr. Drummond received a Ph.D. degree in Biochemistry from Indiana University in 1997, with an emphasis on membrane biochemistry and biophysics. He later joined Hermes Biosciences in 2000 as an Associate Director of Liposomal Research and Development following a post-doc in the laboratory of the renowned father of current liposome drug delivery systems, Demetrios Papahadjopoulos. Overall, Dr. Drummond has more than 20 years of experience in the research and development of advanced drug delivery systems, including four unique drugs that have been tested in various clinical trials, >40 issued patents or patent applications, and more than 65 peer reviewed publications focused on lipid-based nanotherapeutics. The focus of his research is in developing targeted nanotherapeutics for treating a wide range of solid tumors. He successfully developed novel platform technologies for targeting lipidic nanocarriers such as liposomes using a range of novel ligands, but most notably Fab’ or scFv antibody fragments. He has also developed platform technologies for dramatically improving the in vivo drug retention of difficult to stabilize small molecule drugs, and for systemic delivery of nucleic acids. Three of their nanotherapeutics are being studied in clinical trials, including an ErbB2-targeted liposomal doxorubicin which is currently being evaluated in a Phase II study in ErbB2-overexpressing breast cancers and a nanoliposomal formulation of irinotecan which recently showed promising results in a Phase III trial in gemcitabine-refractory pancreatic cancer. A fourth antibody targeted lipososomal drug (MM-310) is scheduled to enter the clinic in the second half of 2016.

Soldano Ferrone

Soldano Ferrone
Professor, Department of Surgery
MGH/Harvard Medical School
Soldano Ferrone
Professor, Department of Surgery
MGH/Harvard Medical School
 
About Speaker:

Soldano Ferrone received his MD and PhD degrees in 1964 and in 1971, respectively, from the University of Milan, Milan, Italy. He has held faculty positions at the University of Milan, Milan, Italy, Scripps Clinic and Research Foundation, La Jolla, CA, Columbia University, New York, NY, New York Medical College, Valhalla, NY, Roswell Park Cancer Institute, Buffalo, NY and at the University of Pittsburgh School of Medicine, Pittsburgh, PA. Since 2012 he is a faculty member of the Department of Surgery at Massachusetts General Hospital, Harvard Medical School, Boston, MA. Dr. Ferrone has received many awards and honors. For the last 30 years he has been the member of many review committees including NIH Study Sections, and of the editorial boards of many scientific journals. Furthermore he is the member of several external scientific boards. Dr. Ferrone’s research program focuses on the molecular characterization of escape mechanism(s) utilized by tumor cells to avoid immune recognition and destruction and on the development of combinatorial immunotherapeutic strategies to counteract the escape mechanism(s) utilized by tumor cells. These studies are greatly facilitated by the large panel of HLA antigen- and human tumor antigen-specific monoclonal antibodies he has developed and shared with the scientific community over the years. He has described the results of his studies in more than 600 papers published in peer reviewed journals. Moreover he has been the editor of 14 books and the guest editor of 5 special issues of oncology journals.

Humphrey Fonge

Humphrey Fonge
Assistant Professor of Medical Imaging
College of Medicine, University of Saskatchewan, Canada
Humphrey Fonge
Assistant Professor of Medical Imaging
College of Medicine, University of Saskatchewan, Canada
 
About Speaker:

Dr. Fonge is an assistant professor of medical imaging at the University of Saskatchewan (UofS) Canada and radiopharmacist at the Royal University Hospital (RUH) - Saskatoon. He is also the nominated head of preclinical molecular imaging program at UofS and the co-director of the Center for Biologics Imaging Research and Development.

Changshou Gao

Changshou Gao
Senior Director/Fellow, Department of Antibody Discovery & Protein Engineering
MedImmune
Changshou Gao
Senior Director/Fellow, Department of Antibody Discovery & Protein Engineering
MedImmune
 
About Speaker:

Changshou Gao Ph.D. is currently a Senior Director/Fellow in the Department of Antibody Discovery and Protein Engineering at MedImmune, a subsidiary of AstraZeneca. Dr. Gao has over 25 years’ experience in recombinant antibody generation (phage, yeast, and mammalian display), antibody engineering, protein expression and antibody drug development and has published over 50 peer-reviewed papers and 30 patent applications. From 1994 to 2002, Dr. Gao received his Ph.D. from and also conducted his postdoc studies at The Scripps Research Institute focusing on catalytic antibodies and antibody discoveries using phage display. Dr. Gao then joined MedImmune in 2002 to establish the phage display capability for lead antibody identification. After a couple of year's effort on antibody lead generation, he is now leading a team responsible for antibody drug conjugates, bispecific antibodies, large scale antibody transient expression, gene therapy, and other new technology development for the next generation of biologics.

Victor-Jeffrey Leyton

Victor-Jeffrey Leyton
Assistant Professor, Department of Nuclear Medicine and Radiobiology
‎Université de Sherbrooke
Victor-Jeffrey Leyton
Assistant Professor, Department of Nuclear Medicine and Radiobiology
‎Université de Sherbrooke
 
About Speaker:

Dr. Leyton trained under world-renowned researchers in the fields of antibody engineering and radioimmunoconjugates obtaining his Doctorate in 2008 from the University of California at Los Angeles followed by postdoctoral training at the University of Toronto. Since 2013, he has been a professor at the Université de Sherbrooke in Québec, Canada and has earned high honors such as Outstanding Canadian New Investigator and National Research Scholar. In addition, his research is federally funded by the Canadian Institutes of Health Research to support his work considered of high scientific caliber that is relevant to a global health need. His laboratory now works in a potential ground-breaking section of antibody-drug conjugate (ADC) research that could propel ADCs into becoming a widespread clinical reality. Specifically, his team researches on technologies that would provide ADCs with better delivery of the chemotherapeutic drugs inside target tumor cells. His approach may change the way we design ADCs in the future.

Ahuva Nissim

Ahuva Nissim
Reader in Antibody and Therapeutic Engineering
Barts and The London, Queen Mary's School of Medicine and Dentistry
Ahuva Nissim
Reader in Antibody and Therapeutic Engineering
Barts and The London, Queen Mary's School of Medicine and Dentistry
 
About Speaker:

Ahuva Nissim graduated in Molecular Immunology in 1992 from the Weizmann Institute of Science in Israel and was trained as a postdoctoral fellow at the MRC Centre for Protein Engineering in Cambridge until 1995. During this period she developed phage display semi-synthetic human antibody library which has been used worldwide. In November 2000 she was appointed as a Senior Lecturer at Queen Mary University. Her studies are interdisciplinary and involve translational research at the William Harvey Research Institute and with intensive worldwide collaborations. Her main research interest focuses on development of targeted immunotherapy, recently highlighted in Nature Review Rheumatology as a basis for development of novel therapy for arthritis (Nature Reviews Rheumatology 10, 511 (2014)  

Andrew Tsourkas

Andrew Tsourkas
Professor, Bioengineering
University of Pennsylvania
Andrew Tsourkas
Professor, Bioengineering
University of Pennsylvania
 
About Speaker:

Andrew Tsourkas, Ph.D. is a Professor of Bioengineering at the University of Pennsylvania in Philadelphia, PA.  Dr. Tsourkas received his Bachelor’s degree in Mechanical Engineering in 1997 from Cornell University, his Master’s degree in 1999 from Johns Hopkins University, and his Ph.D. in Biomedical Engineering from the Georgia Institute of Technology/Emory University joint Ph.D. program in 2002.  He then conducted a post-doctoral fellowship in the Department of Radiology at Harvard University, before joining Penn in 2004. Dr. Tsourkas is currently the co-Director for the Center for Targeted Therapeutics and Translational Nanomedicine. He has over 80 peer-reviewed and invited publications and was a recipient of the Wallace H. Coulter Foundation Early Career Award and the National Science Foundation CAREER Award. In 2015, Dr. Tsourkas was also elected as a fellow to the American Institute for Medical and Biological Engineering. Dr. Tsourkas is an inventor on over a dozen patents and has founded four biotechnology companies.

Novel Protein Therapeutics 2017
DISTINGUISHED SPEAKERS
Sukmook Lee

Sukmook Lee
Principal Investigator, Laboratory of Molecular Cancer Therapeutics
Scripps Korea Antibody Institute
Sukmook Lee
Principal Investigator, Laboratory of Molecular Cancer Therapeutics
Scripps Korea Antibody Institute
 
About Speaker:

Sukmook, Lee is a Principal Investigator of Laboratory of Molecular Cancer Therapeutics in Scripps Korea Antibody Institute (SKAI). He grew up in Korea and received his Ph.D. degree in biochemistry and cellular signaling from the Pohang University of Science and Technology (POSTECH) in 2002. Prior to joining SKAI in 2010, he joined National Institute of Health as a postdoctoral associate and Seoul National University as research associate professor for participating in more than six years research experience in the field of antibody engineering. Currently, Sukmook and his team have been focused on developing therapeutic antibodies against novel cancer targets particularly related to tumor angiogenesis and metastasis in collaboration with a wide range of academic and industrial partners.

Jacob Petersburg

Jacob Petersburg
PhD Candidate - Wagner Laboratory Department of Medicinal Chemistry
University of Minnesota
Jacob Petersburg
PhD Candidate - Wagner Laboratory Department of Medicinal Chemistry
University of Minnesota
 
About Speaker:

Jacob received his B.A. from Saint John’s University in 2011 where he majored in Biochemistry. Following his graduation Jacob worked at Boston Scientific as a product performance analyst for one year prior to continuing his education at the University of Minnesota. He is a Ph.D. Candidate in Medicinal Chemistry where he has trained under the supervision of Dr. Carston Wagner. Jacob’s research focused on the successful development of a novel protein based platform, Prosthetic Antigen Receptors (PARs), for anti-cancer immunotherapy and non-genetic engineering of cell surfaces.

Alyse Portnoff

Alyse Portnoff
Post Doc, Department of Antibody Discovery and Protein Engineering
Medimmune
Alyse Portnoff
Post Doc, Department of Antibody Discovery and Protein Engineering
Medimmune
 
About Speaker:
John Ross

John Ross
Senior Director, Protein Therapeutics
Cue Biopharma
John Ross
Senior Director, Protein Therapeutics
Cue Biopharma
 
About Speaker:

John Ross has been focused on developing protein therapeutics for a number of years (at Genetics Institute (which became Wyeth, and is now Pfizer), Aileron Therapeutics, and Permeon Biologics). He joined Cue Biopharma shortly after its inception in 2015 and is excited to help develop the potentially transformative technology of the company.

Mario Sanches

Mario Sanches
Senior Scientist, Protein Engineering
Zymeworks
Mario Sanches
Senior Scientist, Protein Engineering
Zymeworks
 
About Speaker:

Mario Sanches is a Senior Scientist with the Protein Engineering department at Zymeworks. He has a B.S. degree and an M.S. in Chemistry, and a Ph.D. in Biomolecular Physics from the Sao Paulo University (Brazil). He has an extensive knowledge in structural biology and macromolecular structural characterization and analysis, having held positions as Research Fellow at the Brazilian Synchrotron (Brazil), visiting Research Fellow at the National Cancer Institute at Frederic (USA), and a CCSRI Postdoctoral Research Fellow at the Samuel Lunenfeld Research Institute in Toronto (Canada). Over the past five years Mario has been involved in a number of rational scaffold engineering and drug development efforts, including Zymeworks' Azymetric and AlbuCORE platforms.

Kiyoshi Takayama

Kiyoshi Takayama
Founder, President
NB Health Laboratory
Kiyoshi Takayama
Founder, President
NB Health Laboratory
 
About Speaker:

Kiyoshi Takayama has a Ph.D. in pharmaceutical science from the Graduate School of Pharmaceutical Sciences, University of Tokyo, Japan. He worked for more than 12 years as a research scientist at Taisho Pharmaceutical Co., Ltd, Japan, where he was involved in various drug discovery programs for chronic inflammation and COPD. He also contributed to research on vascular inflammation at Brigham and Women’s Hospital, Harvard Medical School, Boston, USA. After leaving Taisho, Takayama founded NBHL in 2006.

Medha Tomlinson

Medha Tomlinson
Principal Research Scientist
Abbvie
Medha Tomlinson
Principal Research Scientist
Abbvie
 
About Speaker:

Medha Tomlinson received her doctorate in mass spectrometry from the University of Cincinnati and completed her post-doctoral work in protein characterization with Professor Charles Wilkins at the University of California Riverside.  She joined BASF and worked on supporting small molecule projects and her role subsequently expanded to support Biologics programs. She led a group supporting antigen purification and characterization and currently leads the Biologics Protein Purification group at Abbvie within Global Protein Sciences supporting antigen and fusion protein purification for all therapeutic areas.

Wouter Verdurmen

Wouter Verdurmen
Research Associate, Department of Biochemistry
Radboud University Medical Centre
Wouter Verdurmen
Research Associate, Department of Biochemistry
Radboud University Medical Centre
 
About Speaker:

Dr. Verdurmen has done his PhD on the cellular delivery of biomacromolecules at the Radboud University in Nijmegen, the Netherlands, focusing on the use of cell-penetrating peptides. After finishing his PhD cum laude in 2012, he received a postdoctoral fellowship that he used to join the laboratory of Andreas Plückthun in order to work on developing a quantitative assay for measuring cytosolic delivery, which he then employed to investigate engineered modular protein transport systems. In 2016, he received an early career grant to start an independent line of research in Nijmegen, the Netherlands, where he is now further developing therapeutic protein delivery methods and assessing their potential in complex 3D models using microfluidic systems.